Related Experiment Video
Updated: Jun 22, 2026
12:17
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Sutureless aortic valve replacement with the 3f Enable aortic bioprosthesis.
Sven Martens1, Anja Ploss, Sami Sirat
1Department of Thoracic and Cardiovascular Surgery, JW Goethe University Hospital, Frankfurt, Germany. martens.herz@gmx.de
The Annals of Thoracic Surgery
|May 26, 2009
Summary
Sutureless aortic valve replacement using the 3f Enable bioprosthesis is safe and feasible in elderly patients. This novel approach shows promising hemodynamic results and potential for reduced procedure times.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Engineering
- Geriatric Medicine
Background:
- Elderly patients undergoing aortic valve replacement often have comorbidities requiring treatment alternatives.
- Minimizing extracorporeal circuit time and ensuring reliable hemodynamics are crucial in this population.
- The nitinol-stented 3f Enable sutureless bioprosthesis offers a potential solution.
Purpose of the Study:
- To evaluate the clinical feasibility and safety of the sutureless 3f Enable aortic valve prosthesis.
- To assess the hemodynamic performance and procedural characteristics in elderly patients.
- To explore the potential for reduced cardiopulmonary bypass and cross-clamp times.
Main Methods:
- A prospective study involving 32 elderly patients undergoing aortic valve replacement with the 3f Enable prosthesis.
- Procedures utilized cardiopulmonary bypass and cardioplegic arrest.
- Concomitant procedures included mitral/tricuspid valve repair, coronary artery bypass grafting, and subvalvular myectomy.
Main Results:
- Successful implantation in 30 out of 32 patients; two required conversion to standard procedures.
- Mean implantation time was 9 minutes.
- No paravalvular leakage was detected. Mean transvalvular gradients at discharge and 6 months were low (9-10 mmHg mean, 18 mmHg peak).
Conclusions:
- Sutureless aortic valve implantation with the 3f Enable bioprosthesis is feasible and safe in elderly patients.
- Promising hemodynamic outcomes with low gradients observed post-procedure and at 6-month follow-up.
- Increasing experience may lead to further reductions in cardiopulmonary bypass and aortic cross-clamp times.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...